Background Reduction in R-wave amplitude immediately after defibrillation shocks in an integrated shock/sense transvenous cardioverter-defibrillator (TCD) lead system has prompted concerns regarding adequate sensing after failed shocks. We therefore studied redetection characteristics for ventricular fibrillation after unsuccessful defibrillation shocks in a TCD system to determine if these observations have clinical relevance.
Appropriate Sensing of Ventricular Fibrillation
After Failed Shocks in a Transvenous Cardioverter-Defibrillator System Jonathan R. Ellis, MD; David T. Martin, MBBS; Ferdinand J. Venditti, Jr, MD Background Reduction in R-wave amplitude immediately after defibrillation shocks in an integrated shock/sense transvenous cardioverter-defibrillator (TCD) lead system has prompted concerns regarding adequate sensing after failed shocks. We therefore studied redetection characteristics for ventricular fibrillation after unsuccessful defibrillation shocks in a TCD system to determine if these observations have clinical relevance.
Methods and Results Fifty patients with this shock/sense TCD lead system underwent conversion testing of their TCD at several time intervals. There were a total of 142 failed shocks events recorded, including 10, 15, 70, and 47 events at implantation, predischarge, and 2-and 6-month testing, respectively. Initial detection time (IDT) and redetection time (RDT) for ventricular fibrillation were measured from event markers for all unsuccessful defibrillation shocks. To assess the effect of failed shocks on electrogram quality, 54 failed shock episodes were evaluated in 37 of the 50 patients by measuring electrograms during VF before and after shock. Mean RDT for the entire group was 5.3±3.5 seconds compared with an IDT of 4.5±3.3 seconds (P=NS). There were no significant T he implantable cardioverter-defibrillator has proven to be an effective therapy for preventing sudden cardiac death.1'-However, standard implantation techniques that require thoracotomy or sternotomy not only are costly but also are associated with considerable perioperative morbidity.5 The development of a transvenous cardioverter-defibrillator system (TCD) will likely significantly reduce implantation risks and cost. 6, 7 The first Food and Drug Administration (FDA)-approved transvenous lead system uses an integrated tripolar shock/sense lead. Integrated electrode systems use a dual-purpose electrode, which serves as the anode for sensing and the cathode for shock delivery. In this case, the common electrode is the distal electrode, which is the distal shocking electrode (cathode) as well as the indifferent electrode (anode) for sensing. Because of this shared electrode, concern has arisen recently regarding the reliability of sensing in this system.8,9
differences between IDT and RDT at implantation or any follow-up testing period, despite a significant decline in R-wave amplitude from 8.1+3.5 to 6.8±2.8 mV (P<.0001) measured 3 to 6 seconds after shock delivery. Analysis of 8 individuals with any extended RDT (>10 seconds) showed no significant differences in clinical or implantation characteristics when compared with 42 individuals without extended RDT.
Conclusions In this integrated shock/sense TCD lead system, unsuccessful shock delivery has no significant effect on redetection of ventricular fibrillation at device implantation or up to 6 months of follow-up, despite an observed reduction in postshock R-wave amplitude. Therefore, the reported reduction in electrogram quality after a shock is of no practical importance because sensing of ventricular fibrillation does not appear to be compromised in this particular TCD system. Whether this applies to other implantable cardioverter-defibrillator pulse generators and lead systems with different sensing characteristics requires further evaluation. (Circulation. 1994;90:1820-1825.)
Key Words * countershock * ventricular fibrillation a cardioverter-defibrillators, implantable * defibrillation After failed initial shocks for ventricular fibrillation, a reduction in rate sensing endocardial R-wave amplitude has been reported in a preliminary report.8 This is likely secondary to local effects of the high energy delivered in close proximity to the sensing electrodes. Some delay in sensing of ventricular fibrillation was also noted in this small series of patients after an initial unsuccessful shock was delivered.
The objective of our study was to clarify sensing characteristics of an integrated shock/sense transvenous defibrillation system. Specifically, we attempted to determine if the noted decreases in postshock R-wave amplitude result in delayed redetection of ventricular fibrillation.
Methods

Patients
Fifty consecutive patients who underwent successful implantation of a TCD system at our institution from May 1991 through September 1992 were included in this study after giving written informed consent. These patients were part of a phase 2 clinical trial of the efficacy of this lead system sponsored by the manufacturer. This study was approved by the Human Studies Committee of the Lahey Clinic.
Patient demographics are shown in 
Device Description
All patients received an Endotak C transvenous lead system (Model series 0060) and a Ventak P (Model 1555 or 1600) pulse generator (Cardiac Pacemakers Inc). This lead system is composed of a 12F tripolar tined transvenous lead, a Y-connector, and a subcutaneous patch. The 100-cm transvenous lead, which is positioned in the right ventricular apex, is capable of integrated bipolar sensing and defibrillation in a single lead (Fig 1) . Sensing occurs between a distal porous titanium tip and the distal shock/sense electrode beginning 6 mm proximal to the tip electrode. Shocks were delivered via multiple possible electrode configurations, always including the distal shock/sense electrode (Fig 2) . The most common configuration in the study group was 3; this was used in 76% of patients (Table 3) .
Device Implantation
All aspects of device implantation were performed during one procedure in the operating room. All testing during implantation was done with an external cardioverter-defibrillator (ECD) using truncated exponential monophasic shocks. A standard stepdown protocol described previously was used to determine defibrillation threshold (DFT).10 DFT testing started with 20 J, and subsequent attempts were made at levels of 2 to 5 J lower until an unsuccessful shock was delivered. Unsuccessful defibrillation was followed by a 30-J shock using the ECD's automatic mode (requiring redetection), a 40-J rescue shock, or external countershock. All patients had a 
Electrophysiological Evaluation
All patients underwent predischarge and long-term invasive testing in the first 6 months. The purpose of the predischarge test was to demonstrate appropriate system function. One to three tests of ventricular defibrillation were performed in all patients.
The long-term tests were more extensive and were performed in a fashion similar to the protocol during device implantation using the standard stepdown protocol, previously described, to determine DFT. Because threshold testing was done using the generator, the energy levels selected were different. All other aspects of threshold testing were identical. Since the DFT was remeasured, all long-term tests resulted in at least one failed shock requiring redetection of ventricular fibrillation. Again, all failed shock episodes were recorded and analyzed.
Detection Time Measurements
Detection times and RDTs were measured manually by one of the investigators for each episode of failed shock therapy. Tracings with a recorded event marker channel were used to measure the time for both sensing events. Detection time was defined as the time from device activation to detection resulting in device charging for a first shock. RDT was defined as the time from first shock to redetection of ventricular fibrillation resulting in device charging for a second shock (Fig 3) . Morphology and tachycardia cycle length were recorded for all preshock and postshock arrhythmias. Ventricular fibrillation was defined as a rapid polymorphic rhythm with a cycle length .200 mS. Polymorphic ventricular tachycardia was defined as rapid rhythm with a cycle length >200 mS. Episodes of monomorphic ventricular tachycardia were excluded from this analysis.
Electrogram Measurements
In a subgroup of 37 patients, electrogram data were available in 54 episodes of failed shock delivery during implantation. Only episodes using the implanted lead configuration were analyzed. Preshock R-wave amplitude, surface morphology, and cycle length were compared with postshock values measured 3 to 6 seconds after shock delivery. Only polymorphic arrhythmia episodes were analyzed. No 
Results
The 50 patients in this study group had a total of 142 episodes of redetection after failed first defibrillation shocks. There were 10, 15, 70, and 47 failed shock events at implantation, predischarge, and 2-and 6-month follow-up, respectively. There were 68 failed shocks . 20 J and 74 failed shocks <20 J. The mean cycle length of the initial arrhythmia was 186±28.6 versus 188±33.6 mS for the arrhythmia after the failed first shock (P>.10). Ventricular fibrillation was the initial rhythm in 73% of episodes and 75% of postshock rhythms (P>.10).
There was no significant difference between IDT and RDT after failed defibrillation (Table 4 ). This was true for the total group as well as individually at implant testing and the 2-and 6-month testing periods. Although there was a significant difference between IDT and RDT at the predischarge test, the mean IDT was extremely short and the mean RDT was actually lower than for any other testing period. Failure to redetect was not observed during any episode.
RDT was longer than IDT in 70 episodes, less than IDT in 69 episodes, and equal to IDT in 3 episodes. The ranges of IDT and RDT were variable, with the longest IDT being 28 seconds and longest RDT being 28 seconds. There were 5 episodes of IDT of > 10 seconds (3.5%) and 3 episodes of >12 seconds (2%) in 4 and 2 patients, respectively. There were 11 episodes of RDT of >10 seconds (7.8%) in 8 patients and 7 episodes of >12 seconds (3.5%) in 5 patients.
Three of the 4 longest RDT episodes occurred in 1 patient during the 6-month test. This DFT test required 14 shocks for completion of the testing protocol. The longest RDT occurred after multiple shocks had already been delivered during stepdown DFT testing. This patient had marginal DFTs and R waves at implantation. He has been followed for 16 months without a spontaneous event.
To try to identify those individuals with extended RDTs (any RDT >10 seconds), multiple clinical and implant variables were evaluated in univariate fashion. Eight patients had at least 1 episode of extended redetection. There was no significant difference in clinical or implantation characteristics between this group and the remaining 42 patients without extended redetection.
Because many of the shocks delivered were <20 J and less energy may have less effect on R-wave amplitude, a second analysis with shocks >20 J was performed (Table 5 ). These 68 shocks were 48% of the total group. When evaluated as one group or at separate energy levels, there was no difference between IDT and RDT, except for the >30-J group. In this group, the IDT was extremely short, with the RDT falling in the range seen for the other energy levels rather than the difference being secondary to extended redetection.
There were 13 episodes requiring second redetections, where the first two defibrillation shocks were unsuccessful. All second shocks in this group were 30 J. The second RDTs (RDT2) were not significantly different from the IDT or the RDT in this group (5.2±+3.0, 7.2±4.7, and 6.4+5.8 seconds for IDT, RDT, and RDT2, respectively).
Electrogram Data
There were no differences in clinical parameters between the electrogram subgroup and the total group. The mean failed shock energy for this group was 11.4±5.6 J. There was a significant decline in postshock R-wave amplitude in this group, although the absolute decline was less than 1.5 mV (Table 6 ). There was no difference in preshock and postshock cycle length or morphology. There was no correlation between shock energy level and R-wave amplitude changes. In a recent preliminary report, diminished R-wave amplitude was noted in the TCD system used in our study. Electrogram degradation was observed after high-energy shocks (>5 J) but not after low-energy shocks (<5 J).9 A 58% reduction in the amplitude of the initial deflection was noted 3 seconds after a 20-J shock was delivered. Complete recovery of R-wave amplitude took up to 2 minutes.
The most recent report on this particular lead system noted diminished postshock R-wave amplitudes associated with impaired sensing.8 These authors found significantly reduced sinus rhythm endocardial electrogram amplitudes after defibrillation shocks in 5 patients during implantation. The amplitude decreased from an average of 10.5 mV before shock to 6.5 mV 30 seconds after shock (all were 40-J shocks). During predischarge testing, 1 patient had prolonged RDTs of 6 and 7 seconds, and manual defibrillation was required after one prolonged RDT. In 1 additional patient, redetection occurred 12 seconds after the first ineffective shock; however, this patient had a Ventak PRx (Cardiac Pacemakers Inc) that categorized the arrhythmia as a new event delivering the same ineffective therapy. Based on their experience, these authors concluded that sensing was a problem with this integrated shock/sense lead system.
In our study, we found no significant difference in the RDT for ventricular fibrillation after unsuccessful shocks compared with detection time of ventricular fibrillation before shock delivery despite significant R-wave reductions in ventricular fibrillation. There are several explanations for our seemingly discrepant findings. Since the automatic gain feature of the Ventak P generator is capable of sensing R waves as small as 0.3 mV, the reported decline in R wave is still well within this particular device's capabilities. We did find that on occasion there were some increases in RDTs; however, the overall statistical analysis of our large series of episodes demonstrated no trend toward increased RDTs after shock delivery.
The larger sample size of our study may more accurately reflect the function of this system. Our power calculation suggests that this study had a large enough number of episodes to detect a 33% increase in RDTs.
All patients in our series received an FDA-approved generator (Ventak P). Initial detection and redetection use the same criteria (8 beats above the rate cutoff). After a shock, this generator will declare the tachycar- 
